

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hiroshi MORI

SERIAL NO: New U.S. PCT Application Based on PCT/JP03/05017

GAU:

FILED: Herewith

EXAMINER:

FOR: GAMMA-SECRETASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 260276US0PCT		SERIAL NO. 109511269 New U.S. PCT Application Based on PCT/JP03/05017	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroshi MORI			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	236734	09/16/87	EP		NO	
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	GU Y. et al., Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J.Biol.Chem., vol. 276, No. 38, p.35235-8, September 21, 2001					
	AX	SHEARMAN M.S. et al., L-685, 458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry, vol. 39 no. 30, p.8698-704, August 01, 2000					
	AY	WOLFE M.S. et al., A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. J.Med.Chem., vol. 41 no.1. pages 6 to 9, January 01, 1998					
	AZ	SCHWARZE, Steven R. et al., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science vol. 285, pages 1569 to 1572, September 3, 1999				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 260276US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/JP03/05017	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroshi MORI			
				FILING DATE Herewith		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AAA	WEIDEMANN A. et al., A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry, vol. 41 no.8, p.2825-35, February 26, 2002					
	AAB	PINNIX I., et al., A novel gamma-secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. J.Biol.Chem., vol. 276 no.1, p.481-7, January 05, 2001					
	AAC	FIGUEIREDO-PEREIRA M.E. et al., Distinct secretases, a cysteine protease and a serine protease, generate the C termini of amyloid beta-proteins Abeta1-40 and Abeta1-42, respectively. J.Neurochem., vol. 72 no.4, p.1417-22, 1999 April					
	AAD	GHOSH A.K. et al., Structure-based design: potent inhibitors of human brain memapsin 2. (.beta.-secretase). Journal of Medicinal Chemistry, vol. 44 no.18, pages 2865 to 2868, 2001					
	AAE	CHONG K.T. et al., Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities. Journal of Medicinal Chemistry, vol. 36 no.17, p.2575-7, 1993					
	AAF	TIAN G. et al., Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methyl ester, L685458, sulfonamides, and benzodiazepines. J.Biol.Chem., vol. 277 no.35, p.31499-505, August 30, 2002					
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							